Aphria (TSX:APHA): This Pot Stock Ends Volatile Week in the Red

While Aphria (TSX:APHA) stock has disappointed investors with its Q4 results, it remains a top bet among cannabis peers.

edit Colleagues chat over ketchup chips

Image credit: Photo by CIRA/.CA.

Shares of cannabis giant Aphria (TSX:APHA)(NASDAQ:APHA) closed trading at $6.39 on Friday. The pot stock was volatile in the last week as it first gained momentum on an analyst upgrade. Cantor Fitzgerald analyst Pablo Zuanic increased Aphria’s stock price from US$7.86 to US$8.23 and named the marijuana stock as one of his top picks in this segment.

The analyst was bullish on APHA and expected the company to increase sales by 25% on a sequential basis in its fiscal fourth quarter of 2020. However, Aphria disappointed investors when it announced Q4 results and reported a net loss of $98.8 million or $0.39 per share. Aphria had reported a net profit of $5.7 million in the previous quarter.

Aphria’s sales in Q4 stood at $152 million and were up 5% sequentially or 18% year-over-year. The company’s revenue was also higher than analyst estimates of $147 million. However, they forecast Q4 net loss at $0.04. Aphria stock fell close to 20% following its less than impressive earnings, wiping out its gains early last week.

Another reason why APHA stock slumped was the company’s announcement that it filed a prospectus detailing an at-the-market secondary common stock issue, authorizing it to raise $100 million. This potential equity dilution sent the stock spiraling downwards in the second half of last week.

What’s next for Aphria investors?

Despite the company’s disappointing results, Aphria remains a company that is well poised to increase investor wealth in the upcoming decade. There are multiple revenue drivers for the pot stock that include an expanding addressable market, new product categories such as Cannabis 2.0 and line extensions.

Aphria is trading at a market cap of $1.84 billion, and its forward price to sales multiple stands at just 2.6. Comparatively, the company is forecast to expand sales by 28.7% year over year to $699.52 million in fiscal 2021.

Marijuana heavyweight Canopy Growth reported revenue of $107 million in its last quarter and its sales for the current fiscal is forecast at $509.36 million. However, Canopy is valued at a much higher market cap of $9.1 billion.

We can see that Aphria is trading at an attractive valuation. While Aphria reported a loss of $98.8 million in Q4, this was primarily driven by impairment charges amounting to $64 million and changes in fair value of investments that totalled close to $32 million. Excluding these non-recurring charges, Aphria is close to profitability.

Aphria has in fact post a net loss in just three of its last eight quarters, a rarity among pot companies. The company also has a strong balance sheet with close to $500 million in cash, $129.6 million in debt, and $278 million in convertible debentures.

Further, its intention to raise $100 million in a secondary issue will improve liquidity, giving Aphria enough time to improve profit margins in the next few quarters.

The Foolish takeaway

Aphria stock’s recent weakness due to its Q4 results should not deter long-term investors. In fact, Aphria stock is trading 72% below its record high, which should make it attractive to contrarian investors. The company’s low valuation, strong balance sheet, and expanding addressable market make it a winning bet among pot stocks.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »